JPWO2022049614A1 - - Google Patents

Info

Publication number
JPWO2022049614A1
JPWO2022049614A1 JP2020551453A JP2020551453A JPWO2022049614A1 JP WO2022049614 A1 JPWO2022049614 A1 JP WO2022049614A1 JP 2020551453 A JP2020551453 A JP 2020551453A JP 2020551453 A JP2020551453 A JP 2020551453A JP WO2022049614 A1 JPWO2022049614 A1 JP WO2022049614A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551453A
Other languages
Japanese (ja)
Other versions
JP6799831B1 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP2020187708A priority Critical patent/JP7548784B2/ja
Application granted granted Critical
Publication of JP6799831B1 publication Critical patent/JP6799831B1/ja
Publication of JPWO2022049614A1 publication Critical patent/JPWO2022049614A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020551453A 2020-09-01 2020-09-01 Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 Active JP6799831B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020187708A JP7548784B2 (ja) 2020-09-01 2020-11-11 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/032987 WO2022049614A1 (ja) 2020-09-01 2020-09-01 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020187708A Division JP7548784B2 (ja) 2020-09-01 2020-11-11 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Publications (2)

Publication Number Publication Date
JP6799831B1 JP6799831B1 (ja) 2020-12-16
JPWO2022049614A1 true JPWO2022049614A1 (https=) 2022-03-10

Family

ID=73741045

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551453A Active JP6799831B1 (ja) 2020-09-01 2020-09-01 Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
JP2020187708A Active JP7548784B2 (ja) 2020-09-01 2020-11-11 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020187708A Active JP7548784B2 (ja) 2020-09-01 2020-11-11 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物

Country Status (10)

Country Link
US (1) US20230391878A1 (https=)
EP (1) EP4209227A4 (https=)
JP (2) JP6799831B1 (https=)
KR (2) KR102269716B1 (https=)
CN (1) CN116096411A (https=)
AU (1) AU2020466800A1 (https=)
CA (1) CA3189847A1 (https=)
IL (1) IL300694A (https=)
MX (1) MX2023002482A (https=)
WO (1) WO2022049614A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CN120441701A (zh) * 2024-02-07 2025-08-08 武汉人福创新药物研发中心有限公司 一种靶向il-31ra的抗体或其抗原结合片段及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
JP2002338476A (ja) * 2001-05-21 2002-11-27 Health Factor Kenkyusho:Kk 腎透析に伴う痒みの予防治療剤
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
CN101589060A (zh) * 2006-01-10 2009-11-25 津莫吉尼蒂克斯公司 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法
EP2749571A3 (en) * 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2548714T3 (es) 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TW201537175A (zh) * 2013-06-28 2015-10-01 Chugai Pharmaceutical Co Ltd 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法
WO2015025767A1 (ja) * 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
US20190135804A1 (en) * 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
KR102156932B1 (ko) * 2017-11-23 2020-09-17 주식회사 헬릭스미스 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물
BR112020021739A2 (pt) * 2018-04-25 2021-01-26 Kiniksa Phamaceuticals, Ltd. tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta

Also Published As

Publication number Publication date
US20230391878A1 (en) 2023-12-07
CA3189847A1 (en) 2022-03-10
MX2023002482A (es) 2023-03-08
EP4209227A1 (en) 2023-07-12
IL300694A (en) 2023-04-01
CN116096411A (zh) 2023-05-09
JP2022041802A (ja) 2022-03-11
EP4209227A4 (en) 2024-05-29
KR20230048233A (ko) 2023-04-11
JP7548784B2 (ja) 2024-09-10
WO2022049614A1 (ja) 2022-03-10
KR102269716B1 (ko) 2021-06-28
JP6799831B1 (ja) 2020-12-16
KR102800698B1 (ko) 2025-04-24
AU2020466800A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
JPWO2022049614A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200923

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200923

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201111

R150 Certificate of patent or registration of utility model

Ref document number: 6799831

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250